Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Yehua Shen

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5110364123. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 2 papers

Papers 12

  1. Digital subtraction angiography-guided pancreatic arterial infusion of GEMOX chemotherapy in advanced pancreatic adenocarcinoma: a phase II, open-label, random… Co-author DOI 10.1186/s12885-024-12695-8↗
  2. SUMO3 inhibition by butyric acid suppresses cell viability and glycolysis and promotes gemcitabine antitumor activity in pancreatic cancer. Last author DOI 10.1186/s13062-024-00513-x↗
  3. Combined ablation-chemotherapy versus chemotherapy alone for pancreatic cancer with liver metastasis: a propensity score matching study. Co-author DOI 10.1080/17474124.2021.1869937↗
  4. miR-939-5p Contributes to the Migration and Invasion of Pancreatic Cancer by Targeting ARHGAP4. Co-author DOI 10.2147/ott.s227644↗
  5. ARHGAP4 regulates the cell migration and invasion of pancreatic cancer by the HDAC2/β-catenin signaling pathway. Co-author DOI 10.1093/carcin/bgz067↗
  6. ARHGAP4 mediates the Warburg effect in pancreatic cancer through the mTOR and HIF-1α signaling pathways. Co-author DOI 10.2147/ott.s207560↗
  7. Prognostic values of common clinical parameters in advanced pancreatic ductal adenocarcinoma: a large multicenter cohort study of ten years. Co-author PMID 29641971↗
  8. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Co-author DOI 10.1002/cncr.30057↗
  9. Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter coh… Co-author DOI 10.18632/oncotarget.13000↗
  10. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Co-author DOI 10.1007/s13277-015-3097-8↗
  11. High expression of erythropoietin-producing hepatoma cell line-B2 (EphB2) predicts the efficiency of the Qingyihuaji formula treatment in pancreatic cancer CFP… Co-author DOI 10.3892/ol.2014.2134↗
  12. Safety evaluation of high-intensity focused ultrasound in patients with pancreatic cancer. Co-author DOI 10.1159/000348530↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhiqiang Meng · 8 shared papers, 2013–2021 · strength 0.62
  2. Gang Chen · 3 shared papers, 2019–2024 · strength 0.50
  3. Changjing Huang · 2 shared papers, 2024 · strength 0.46
  4. Zhen Chen · 6 shared papers, 2013–2024 · strength 0.43
  5. Liping Zhuang · 4 shared papers, 2016–2021 · strength 0.43
  6. Huifeng Gao · 3 shared papers, 2013–2024 · strength 0.42
  7. Hao Chen · 4 shared papers, 2014–2024 · strength 0.42
  8. Yongqiang Hua · 4 shared papers, 2014–2024 · strength 0.41
  9. Luming Liu · 4 shared papers, 2015–2019 · strength 0.33
  10. Zhouyu Ning · 3 shared papers, 2016–2021 · strength 0.27
  11. Peng Wang · 2 shared papers, 2016–2024 · strength 0.26
  12. Liming Zhu · 1 shared paper, 2024 · strength 0.26
  13. Lanyun Feng · 2 shared papers, 2016–2024 · strength 0.24
  14. Chien‐shan Cheng · 1 shared paper, 2024 · strength 0.20
  15. Zhiqiang Meng · 1 shared paper, 2024 · strength 0.20
  16. Luming Liu · 2 shared papers, 2016–2020 · strength 0.17
  17. Hao Chen · 3 shared papers, 2015–2016 · strength 0.15
  18. Yan Xia · 1 shared paper, 2021 · strength 0.13
  19. Ye Li · 1 shared paper, 2020 · strength 0.13
  20. Lei Wang · 2 shared papers, 2016–2018 · strength 0.11
  21. Chenyue Zhang · 2 shared papers, 2016–2018 · strength 0.11
  22. Shu Dong · 2 shared papers, 2016–2018 · strength 0.11
  23. Yuanbiao Guo · 2 shared papers, 2016–2018 · strength 0.11
  24. Jinming Yu · 2 shared papers, 2016–2018 · strength 0.11
  25. Qiwen Chen · 2 shared papers, 2016–2018 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.